NHS England has announced that the three-year PrEP IMPACT trial testing the efficacy of a combination of tenofovir and emtricitabine in pre-exposure HIV prophylaxis will start enrolment from early September, with full roll-out in English clinical centers expected by April 2018 at the latest.
The £10m PrEP IMPACT trial, described as “the largest single study of its type in the world,” will use Mylan’s generic version of Gilead’s originator drug Truvada, following the conclusion...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?